Prochloraz

CASRN 67747-09-5

  • IRIS Summary (PDF) (13 pp, 114 K)
  • Status: Prochloraz is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (13 pp, 114 K) last updated: 01/01/1989

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
9 x10-3 Hepatic Increase in SAP and liver weights, liver histopathology NOEL : 9.0 x10-1
mg/kg-day
100 High

Reference Concentration for Inhalation Exposure (RfC) (PDF) (13 pp, 114 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (13 pp, 114 K) last updated: 10/01/1989

WOE Characterization Framework for WOE Characterization
C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Statistically significantly increased incidence and dose-related trend in liver adenomas and carcinomas (combined) in both sexes of one strain of mouse.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (13 pp, 114 K)

Oral Slope Factor: 1.5 x10 -1 per mg/kg-day
Drinking Water Unit Risk: 4.3 x10 -6 per µg/L
Extrapolation Method: Male mice: time-to-tumor linearized multistage procedure in dose, Weibull in time. Female mice: linearized multistage procedure
Tumor site(s): Hepatic
Tumor type(s): Liver adenoma/ carcinoma combined (Nor-Am Chemical Co., 1983)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (13 pp, 114 K)

Not Assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.